Recombinant replication competent viruses comprising coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells

By integrating a GSK3 protein coding sequence into adenoviruses, the replication and cytotoxicity of adenoviruses are selectively enhanced in cancer cells, addressing the inefficiencies of current therapies and improving cancer treatment outcomes.

JP2024161491AInactive Publication Date: 2024-11-19ORCA THERAPEUTICS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024135601
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-08-31
Filing Date
2024-08-15
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer therapies using replication-competent adenoviruses lack the ability to selectively target and replicate within cancer cells, leading to potential harm to normal cells and inefficient treatment outcomes.

Method used

Incorporating a glycogen synthase kinase-3 (GSK3) protein coding sequence into the adenoviral genome, operably linked to an expression control sequence, enhances the virus's ability to replicate and kill cancer cells while sparing normal cells by exploiting the differential expression and activity of GSK3 in tumor cells.

Benefits of technology

The modified adenovirus demonstrates selective replication and cytotoxicity in cancer cells, inducing apoptosis and enhancing oncolytic properties, thereby improving cancer treatment efficacy with reduced impact on healthy cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161491000015
    Figure 2024161491000015
  • Figure 2024161491000016
    Figure 2024161491000016
  • Figure 2024161491000017
    Figure 2024161491000017
Patent Text Reader

Abstract

To provide an adenovirus that is promoted in replication and / or its oncolytic properties, and a method for the treatment of cancer in individuals.SOLUTION: The invention relates to recombinant replication competent adenovirus that can replicate and lyse in a host cell comprising in the genome of the adenovirus a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence. It also relates to means and methods for treatment of cancer with a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence, preferably in the context of an adenovirus.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Glycogen synthase kinase-3 (GSK3) is a multifunctional enzyme involved in diverse cellular processes, such as cell proliferation, apoptosis, neuronal function, metabolism, embryonic development, and insulin signaling (1, 2). There are two known isoforms of this protein: GSK3-alpha and GSK3-beta. The enzyme is activated or inactivated through phosphorylation at various residues. The two isoforms have similar structures but distinct cellular functions and are encoded by different genes (3).

[0002] One mode of activation and inactivation of the protein occurs through post-translational phosphorylation of tyrosine (Y) and serine (S) residues. GSK3-alpha and GSK3-beta are believed to be active in unstimulated resting cells. Both isoforms can also autophosphorylate residues Y279 in GSK3-alpha and Y216 in GSK3-beta. Phosphorylation at these positions is known to increase the catalytic activity of the protein. Phosphorylation of S21 in GSK3-alpha and S9 in GSK3-beta can inactivate the respective proteins; these phosphorylated residues can block substrate binding sites, thereby inhibiting GSK3 functionality (4, 5).

[0003] Deregulation of GSK3 has been implicated in a variety of diseases, most notably neurodegenerative disorders, diabetes, and several cancers (1, 2). Its overexpression and its involvement in tumor promotion or suppression have been reported, which may depend on the cell type and phosphorylation state (6-8).

[0004] Overexpression of GSK3 has been described in several types of tumors, where it may act as a tumor promoter promoting survival, cell growth and angiogenesis (9, 10).GSK3 is thought to be a tumor promoter in glioblastoma multiforme, pancreatic cancer, colorectal cancer, renal cancer, leukemia and ovarian cancer (5).

[0005] Inactivation of GSK3-beta has been reported in many types of cancer, and GSK3-beta is thought to be a tumor suppressor in skin, breast, oral and lung cancers (5, 11-13).

[0006] One way to produce a constitutively active form of GSK3-beta is by replacing serine with alanine at position 9 (S9A-GSK3-beta), which prevents the formation of phosphorylated serine at that position that can inactivate the protein. Several groups have designed small molecules to inhibit GSK3-beta activity in those cancers where GSK3 is known to be pro-tumorigenic (14-16).

[0007] Replication competent adenoviruses have recently attracted renewed interest as oncolytic agents in cancer therapy. Current approaches use modifications in the adenovirus genome that promote preferential viral replication in tumor cells as opposed to normal cells. In this respect, the adenovirus mutant "ONYX-015" and Delta24 adenoviruses can serve as prototypes. The ONYX-015 virus has a deletion in the region encoding the E1B 55 kDa protein. As a result, the virus is unable to downregulate p53 activity, which is necessary for efficient viral replication. The Delta24 virus has a deletion in the viral E1A gene, which encompasses the region involved in binding the RB protein. RB binding is necessary for efficient replication in RB-containing cells. Summary of the Invention [Problem to be solved by the invention]

[0008] The present invention is the first in which GSK3 is used to promote the replication of adenovirus and / or its oncolytic properties, which is used in the present invention, for example, to promote the killing of infected tumor cells and for the treatment of cancer. [Means for solving the problem]

[0009] The present invention provides a replication-competent recombinant adenovirus comprising within the adenoviral genome a coding sequence for glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence.

[0010] Also provided is a method of treating cancer in an individual in need thereof comprising administering to said individual an adenovirus of the present invention.

[0011] Further provided is an adenovirus of the invention for use in treating an individual with cancer.Further provided is a method of killing cancer cells comprising providing an adenovirus of the invention to a tumor containing said cancer cells.

[0012] Also provided is a method for increasing the replication rate of a replication-competent recombinant adenovirus in a permissive cell, the method comprising providing a coding sequence for a GSK3 protein operably linked to an expression control sequence in the genome of the adenovirus for expression in the cell.

[0013] Further provided is a method for increasing the oncolytic properties of a replication-competent oncolytic recombinant adenovirus, comprising providing a coding sequence for a GSK3 protein operably linked to an expression control sequence in the genome of the adenovirus for expression thereof.

[0014] In a further aspect, there is provided a method for increasing the rate of replication and spread of a replication-competent recombinant adenovirus in a tumor, comprising providing an oncolytic virus with a coding sequence for a GSK3 protein operably linked to an expression control sequence for expression in cells of the tumor.

[0015] Also provided is a method of using a coding sequence for a GSK3 protein operably linked to an expression control sequence to express the coding sequence to increase the replication rate of a recombinant adenovirus.

[0016] Further provided is a combination comprising an adenovirus of the invention and a further medicament, preferably a cancer drug.

[0017] The invention also provides a method of treatment, or an adenovirus of the invention for use in said treatment, wherein the treatment further comprises the administration of concurrent or sequential radiation therapy, antibody therapy, chemotherapy, cell therapy, immunotherapy, or other anti-cancer intervention or treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] GSK3-alpha is also known by the names, for example, glycogen synthase kinase 3 alpha; serine / threonine protein kinase GSK3A; GSK3 alpha; and glycogen synthase kinase-3 alpha. Reference sequences for GSK3 alpha can be found under the following accession numbers: HGNC: 4616; Entrez Gene: 2931; Ensembl: ENSG00000105723; OMIM: 606784, or UniProtKB: P49840. GSK3-beta is also known by the names, for example, glycogen synthase kinase 3 beta; serine / threonine protein kinase GSK3B; GSK3 beta; glycogen synthase kinase-3 beta; and GSK3 beta isoform. Reference sequences for GSK3 beta can be found under the following accession numbers: HGNC: 4617; Entrez Gene: 2932; Ensembl: ENSG00000082701; OMIM: 605004; and UniProtKB: P49841. The reference sequences are provided only to identify the gene. It is not intended that the gene necessarily have exactly the same sequence as shown for each accession code in the database. Natural and recombinant variants of the sequence are encompassed by the gene name.

[0019] The GSK3 protein encoded by the adenovirus described herein is preferably a GSK3-beta protein.The GSK3 protein is preferably a constitutively active mutant protein.In this regard, the GSK3 protein is preferably a GSK3-beta protein in which the serine residue at position 9 is replaced by another amino acid residue, preferably an alanine residue.

[0020] The coding sequence of GSK3 typically comprises a cDNA of the gene. The cDNA is typically shorter than the genomic sequence, and shorter sequences are preferred in recombinant viruses. On the other hand, expression in cells is typically enhanced by the presence of one or more introns. Such introns may be natural introns of the GSK3 gene. Preferably, the intron is an artificial intron, preferably an artificial intron introduced into the 5'-non-coding region of the pre-mRNA that contains the coding region.

[0021] The coding region is preferably operably linked to an expression control sequence, such as a promoter. A promoter is typically linked to an enhancer sequence. The combination of a promoter and an enhancer is often collectively referred to as a promoter. The promoter is a promoter that is active in tumor cells. Preferred promoters are the CMV promoter, the SV40 promoter, or a housekeeping gene promoter, such as the PGK promoter. The expression control sequence can also be an endogenous viral promoter, such as the endogenous major late promoter (MLP) of adenovirus serotype 5. In this case, the coding sequence can be operably linked to the MLP by alternative splicing into an inserted splice acceptor site, for example similar to the splice acceptor site of the adenovirus serotype 40 long fiber gene (Carette et al., J Gene Med. 2005 Aug;7(8):1053-62).

[0022] The present invention provides a recombinant virus comprising a nucleic acid molecule comprising a GSK3-beta coding region operably linked to a promoter. The recombinant virus is preferably an adenovirus (Ad), herpes simplex virus (HSV), vaccinia virus, poliovirus, reovirus, vesicular stomatitis virus (VSV), semliki forest virus, seneca virus, or maraba virus. The virus is preferably a replication competent virus. Replication competent viruses, such as the replication competent recombinant adenoviruses described herein, can replicate in and lyse cancer cells. Replication competent in the context of the present invention refers to a virus that possesses all the necessary mechanisms to replicate in permissive cells. Replication competence is further illustrated using adenovirus as an example. The same principle applies to other viruses. The replication-competent adenovirus does not require the assistance of additional adenoviral proteins in packaging cells. For example, E1-deleted replication-deficient adenoviruses require a complementing cell that provides E1 protein in trans for efficient replication. Many replication-competent adenoviruses replicate more efficiently in cancer cells than in normal cells. Interest in such viruses increased with the first recombinant adenoviruses that were modified to enhance preferential replication in cancer cells. The modifications include modifications of the viral genome such that one or more parts necessary for efficient replication of the adenovirus in normal cells but not in cancer cells are modified, removed, or otherwise engineered to not be expressed in normal cells. Adenoviruses that replicate preferentially in cancer cells are also called "oncolytic viruses".Oncolytic virus as used herein refers to an adenovirus that preferentially kills cancer cells compared to non-cancer cells. In a preferred embodiment, the replication-competent adenovirus described herein comprises a modification in the viral genome that allows preferential replication of the adenovirus in tumor cells. The modification is preferably a mutation in the viral genome. The mutation is preferably in the E1A region, the E1B region, the E4 region, or a combination of one or more thereof. Many oncolytic viruses comprise mutations in one or more of these regions. The adenovirus according to the invention preferably has a mutation in the E1A region, preferably an E1A region encompassing at least a portion of the CR2 domain of E1A, preferably a deletion encompassing amino acids 122-129 (LTCHEAGF) of E1A. Such a deletion is referred to as a delta 24 deletion. An example of E1A with the indicated E1a-delta 24 mutation is shown in positions 1551-2512 of SEQ ID NO:5. The term gene or region as used herein includes the complete genomic region required for the expression of a gene, including, for example, enhancer regions, promoter regions, and intron or exon sequences. Another mutation that allows preferential replication in tumor cells is the elimination of protein E1b-55K or at least its expression. E1b-55K inactivates p53, induces entry into the S phase of the cell cycle in infected cells, and prevents cell apoptosis. An adenovirus mutated in E1b-55K is known as Onyx-015. This virus has been used to treat tumors defective in p53. Adenoviruses with the delta 24 mutation mentioned above achieve selective replication in tumors in a different manner. The delta 24 mutation affects the conserved region 2 (CR2) of E1a. This E1a region mediates binding to proteins of the retinoblastoma (Rb) family. The pRb protein blocks the transition from the Go / G1 to the S phase of the cell cycle and forms a complex transcription inhibitor with E2F. When E1a binds to pRb, the E2F transcription factor of the pRb-E2F complex is released, and E2F acts as a transcription activator of genes involved in progression to the S phase and viral genes, such as E2.Therefore, the release of E2F is a critical step in the replication of the adenovirus. In tumor cells, cell cycle is uncontrolled because pRb is absent or inactivated by hyperphosphorylation and E2F is free. In these cells, the inactivation of pRb by E1a is no longer necessary. Therefore, adenoviruses with mutations in CR2 grow in cells where E2F is free, such as many cancer cells, and replicate much less efficiently in normal cells with functional pRb.

[0023] Preferential replication can also be achieved by replacing the viral promoter with a tumor-selective promoter. In this embodiment, the modification includes the promoter of tissue- or cell type-specific expression of E1A or E1B. An example is a modification in which the E1a promoter is replaced with another promoter. Various promoters have been used to this effect, such as the alpha-fetoprotein promoter, the prostatic-specific antigen (PSA) promoter, the kallikrein promoter, the mucin 1 promoter, or the osteocalcin promoter. Such adenoviruses replicate more efficiently in (certain) tumor cells, but there is also some replication in normal cells as a result of the incomplete blocking of the replacement promoter. Recently, there are recombinant adenoviruses in which more than one early region promoter is replaced by a tumor cell-selective promoter. Regulation of various viral genes can be performed with different promoters for each viral gene, such as the E2F1 promoter for E1a and the telomerase promoter for E4. In this case, the two promoters must be expressed at a suitable level to allow viral replication so that oncolytic efficacy is retained in many tumor cells. Alternatively, two viral genes can be regulated by the same promoter, for example in the oncolytic virus Onyx 411, E1a and E4 are controlled by the E2F1 promoter.

[0024] In some embodiments, preferential replication is achieved by replacing the viral promoter for a replication essential viral gene with a tumor-selective promoter. A particular embodiment of the present invention includes an oncolytic viral vector whose replication is restricted to cells with a deregulated p16 / Rb pathway by selectively expressing an adenoviral E1 protein, preferably an E1A protein, by replacing all or part of the E1A promoter with an E2F (e.g., E2F1) responsive promoter. In a preferred embodiment, the E1A gene is operably linked to the E2F1 promoter. Preferential replication can also be achieved by combining one or more different means to achieve selectivity. A preferred combination is the E2F1 promoter controlling the E1A gene together with the delta24 mutation (Majem et al., Cancer Gene Ther. 2006 Jul;13(7):696-705 and Alonso et al., Cancer Res. 2007 Sep 1;67(17):8255-63).

[0025] In another aspect, the modification includes a mutation in the nucleic acid sequence in the E3 region or a deletion of the entire E3 region. The mutation in the E3 region can enhance the oncolytic effect of replication-competent adenovirus. One such mutation is a mutation in the endoplasmic reticulum retention domain of E3-19K. The E3-19K protein is known to regulate the presence of MHC-I on the cell membrane. One function of the protein is related to binding to MHC-I, and another function is related to the retention of the E3-19 protein and its associated MHC-I in the endoplasmic reticulum. Expression of E3-19k in cells prevents the translocation of MHC-I to the plasma membrane and the presentation of antigens associated with MHC-I. Thus, expression of E3-19K is associated with a reduced immune response to adenovirus-infected cells. On the other hand, it has been found that a mutation in E3-19K that prevents retention of E3-19K in the endoplasmic reticulum can increase the oncolytic ability of the adenovirus. In one embodiment, the adenovirus of the present invention comprises a modified E3 region. The modification can be a deletion of one or more parts or the whole of the E3 region. In one embodiment, the modification comprises a mutation in the E3-19K protein that prevents retention of E3-19K in the endoplasmic reticulum. In particular, the carboxy-terminal domain of E3-19K is deleted or modified to prevent retention of E3-19K in the endoplasmic reticulum and cause its translocation to the plasma membrane. Adenoviruses that replicate and contain this specific mutation of E3-19K are released more efficiently from infected cells. This increased release causes a higher oncolytic effect. This enhanced oncolytic effect is useful for treating cancer. Preferred mutations in E3-19K are described in WO 2008 / 110579, which is incorporated herein by reference. Suitable E3 mutations are described and exemplified therein by SEQ ID NOs: 1, 2, 4 and 5. The sequences are restated herein as SEQ ID NOs: 1, 2, 3 and 4. The replicative adenovirus of the invention preferably expresses E3-19K comprising a carboxy-terminal part having SEQ ID NO: 4.In another embodiment of the invention, the replicative adenovirus comprises at least the nucleotide sequences SEQ ID NO: 1, SEQ ID NO: 5 and SEQ ID NO: 6. In one embodiment, the replicative adenovirus of the invention expresses E3-19K comprising a carboxy-terminal part having SEQ ID NO: 2, an insertion of an RGD motif in the fiber protein (as defined in positions 1648-1656 of SEQ ID NO: 6); and control regions conferring selective replication of the adenovirus in tumor cells, the control regions being present in the DM1 insulator (as defined in positions 367-1095 of SEQ ID NO: 5), a fragment of the E2F1 promoter (as defined in positions 1282-1545 of SEQ ID NO: 5), a ccacc Kozak sequence (as defined in positions 1546-1550 of SEQ ID NO: 5), and the adenovirus E1a-delta24 mutant gene (as defined in positions 1551-2512 of SEQ ID NO: 5). Another object of the invention is a replicative adenovirus comprising a mutation in the endoplasmic reticulum retention domain of E3-19K that prevents retention of E3-19K in the endoplasmic reticulum, the adenovirus comprising the nucleotide sequence SEQ ID NO: 1. In another aspect of the invention, the replicative adenovirus expresses E3-19K comprising a carboxy-terminal part having SEQ ID NO: 2. In one embodiment, the replicative adenovirus is ORCA-10 as described in Dong, W et al. (2014, Human Gene Therapy 25: 897-904). The GSK3 beta coding region is preferably inserted as a cDNA as shown in Figure 5 or Figure 6. The GSK3 beta is preferably a constitutively active GSK3 beta. The constitutively active GSK3 beta is preferably a GSK3 beta in which the serine residue at position 9 is replaced by another amino acid residue. The GSK3 beta mutant is preferably an S9A mutant, where S is serine and A is alanine.

[0026] Adenoviruses according to the invention may include modifications that increase their replication potential, such as, for example, retention of the E3 region (Suzuki et al., Clin. Cancer Res. 8(2002):3348-3359) or deletion of the E1B-19K gene (Sauthoff et al. Hum. Gene Ther. 11(2000):379-388), or that increase replication selectivity for a particular type of cell, such as, but not limited to, modifications to promote selective expression of early region genes in cancer cells, or modifications that reduce or enhance immunogenicity (i.e., their ability to induce an immune response when introduced into an animal body), such as, for example, retention of the E1B region (Wang et al., Nature Biotechnol. 21(2003):1328-1335).

[0027] Tumor therapy is based on drugs and treatments that selectively kill tumor cells. Such treatments aim to spare normal "healthy" cells as much as possible. The tumor cells can die as a result of cytopathic effects caused by the internal replication of the virus, as a result of the expression of additionally introduced genes, as a result of immune responses to the tumor cells and / or other causes (such as, but not limited to, one or more additional toxic substances associated with the virus). The lysis of tumors is called oncolysis. Adenoviruses that selectively replicate in tumors are called oncolytic viruses. Oncolytic viruses are replication-competent adenoviruses that have been developed to replicate preferentially in cancer cells. Replication is preferential for cancer cells if the virus replicates 20%, preferably 30%, 40%, 50%, 80%, more preferably 100% faster in the cancer cells than in healthy cells derived from the same cell type from which the cancer cells originated.

[0028] The present invention further provides a method for treating cancer in an individual, comprising administering to an individual in need of treatment a replication-competent recombinant adenovirus comprising within the adenoviral genome a coding sequence for Glycogen Synthase Kinase-3 (GSK3) protein operably linked to an expression control sequence.

[0029] The term cancer (also synonymous with "cancer") refers to malignant primary and / or metastatic cancer. Examples of cancer include, but are not limited to, carcinoma; sarcoma, lymphoma, leukemia, melanoma, or myeloma. The cancer is preferably bone cancer, brain cancer, eye cancer, breast cancer, skin cancer, such as melanoma, head and neck squamous cell carcinoma (HNSCC), bladder cancer, lung cancer, ureter cancer, urethra cancer, thyroid cancer, parathyroid cancer, salivary gland cancer, kidney cancer, prostate cancer, cervical cancer, ovarian cancer, and reproductive system cancer, including testicular cancer, endometrial cancer, blood / blood system cancer, or cancer in gastrointestinal tissue, such as colon cancer. In a preferred embodiment, the cancer is prostate cancer, skin cancer, lung cancer, or pancreatic cancer. The host cell is preferably a cancer cell. The cancer cell is preferably a malignant primary and / or metastatic cancer cell. The cancer cells can be carcinoma cells; sarcoma cells, lymphoma cells, leukemia cells, melanoma cells, or myeloma cells. The cancer cells can also be bone cancer cells, brain cancer cells, eye cancer cells, breast cancer cells, skin cancer cells, such as melanoma cells or HNSCC cells, reproductive system cancer cells, including bladder cancer cells, lung cancer cells, ureter cancer cells, urethral cancer cells, thyroid cancer cells, parathyroid cancer cells, salivary gland cancer cells, renal cancer cells, prostate cancer cells, ovarian cancer cells, and testicular cancer cells, endometrial cancer cells, blood / blood system cancer cells, or cancer cells in gastrointestinal tissue. A tumor typically includes cancerous cells and supporting cells, such as stromal cells, vascular cells, blood and / or immune cells. The term cancer cells refers to cancerous cells and does not refer to supporting cells. The replication-competent adenovirus can also infect and replicate in supporting cells. The terms tumor and cancer are used interchangeably herein.

[0030] The cancer cells are preferably cancer cells that do not express GSK3 or that do not overexpress GSK3. The non-expressed or non-overexpressed GSK3 is preferably GSK3 beta.

[0031] The GSK coding region in the adenovirus of the invention preferably comprises a constitutively active form of GSK3, which is preferably a mutant having an activating mutation at position S21 of GSK3 alpha, or at position S9 of GSK3 beta, which activating mutation is preferably a replacement of a codon for a serine residue (at position 21 or position 9, respectively) with a codon for an alanine residue at the indicated positions.

[0032] The present invention also provides a method for increasing the replication rate of a replication-competent recombinant adenovirus in a permissive cell, comprising providing a coding sequence for a GSK3 protein operably linked to an expression control sequence in the genome of the adenovirus for expression in the cell. A measure for the replication rate is the time it takes for an adenovirus-infected cell to show a cytopathic effect (CPE). The replication rate can also be measured by measuring the number of infectious particles produced at a certain time point after infection. Replication rate is typically evaluated relative to another adenovirus. When two different viruses are tested in parallel under otherwise identical conditions, the virus that shows the fastest increase in the number of infectious viral particles produced or the fastest induction of CPE has a higher replication rate. A cell is a permissive cell if it supports the replication of a replication-competent adenovirus as described herein.

[0033] The present invention also provides a method for increasing the oncolytic properties of a replication-competent oncolytic recombinant adenovirus, comprising providing a coding sequence for a GSK3 protein operably linked to an expression control sequence in the genome of the adenovirus for expression of the coding sequence.

[0034] The present invention further provides a method for increasing the rate of replication and spread of a replication-competent recombinant adenovirus in a tumor, comprising providing an oncolytic virus with a coding sequence for a GSK3 protein operably linked to an expression control sequence for expression in cells of the tumor.

[0035] The adenoviruses described herein can carry one or more coding regions for additional transgenes. Examples of suitable additional transgenes are IL2, GM-CSF, and TNF-alpha. Other suitable transgenes are described elsewhere herein.

[0036] Human adenoviruses can currently be subdivided into 7 species (A to G) and 57 different (sero)types.

[0037] The different serotypes are currently classified as follows: Species A: serotypes 12, 18, 31; B species: serotypes 3, 7, 11, 14, 16, 21, 34, 35, 50, 55; C species: serotypes 1, 2, 5, 6, 57; D species: serotypes 8~10, 13, 15, 17, 19, 20, 22~30, 32, 33, 36~39, 42~49, 51, 53, 54, 56; E species: serotype 4; F species: serotypes 40, 41; and G species: serotype 52

[0038] The adenovirus of the present invention is preferably a B, C, or D adenovirus, preferably a B or C adenovirus. The adenovirus is preferably a C type adenovirus. The adenovirus is preferably an adenovirus of serotype 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 19, 20, 21, 22-30, 32, 33, 34, 35, 36-39, 42-49, 50, 51, 53, 54, 55, 56, or 57. In a preferred embodiment, the adenovirus is an adenovirus of serotype 1, 2, 3, 5, 6, 7, 11, 14, 16, 21, 34, 35, 50, 55, or 57. The adenovirus is preferably an adenovirus of type 1, 2, 5, 6, or 57, preferably an adenovirus of type 2 or 5. It is not difficult to make chimeric adenoviruses that contain a portion from one adenovirus serotype and another portion from another serotype. Chimeric adenoviruses that contain portions of serotypes of the same species are known. For example, chimeric serotype 2 and 5 viruses. Chimeric viruses that contain early genes of one serotype and late genes of another serotype are also contemplated. Adenoviruses that contain chimeric adenovirus proteins are also known. For example, chimeric adenovirus fiber proteins in which the fiber shaft and knob domains of adenovirus 5 are genetically replaced with the corresponding domains from adenovirus 3, adenovirus 11, or adenovirus 35 are described in Murakami et al. (2010, Prostate Vol 70(4):pp 362-376). These particular chimeric adenoviruses have altered target cell tropism when compared to Adenovirus 5.

[0039] The adenovirus is preferably a virus based on adenovirus serotype 5, adenovirus serotype 24, adenovirus serotype 35, or adenovirus serotype 51, or a chimeric adenovirus, for example a chimeric adenovirus based on serotype 5 with serotype 35 tropism by replacing part of the serotype 5 fiber with part of the fiber of serotype 35. The adenovirus further provides for the expression of a therapeutic transgene, for example, preferably p53, a tumor antigen, or a secreted protein, for example a growth factor, a cytokine, or a chemokine. The adenovirus is replication competent, in particular oncolytic. The adenovirus is a human or primate adenovirus for infection of and replication in human and primate cells. The adenovirus is another mammalian adenovirus, for example a canine or equine adenovirus for infection of and replication in canine or equine cells, respectively.

[0040] A preferred adenovirus according to the invention is a human adenovirus, preferably a human adenovirus of serotype 5.

[0041] Replication-competent adenoviruses can replicate in many different cells in an animal body, provided that they are derived from an adenovirus with the correct species tropism and that the cells express a surface receptor for the adenovirus. Specific cell surface recognition by recombinant adenoviruses, including replication-competent adenoviruses, can be altered by pseudotyping or targeting, as known to those skilled in the art.

[0042] The present invention further provides an adenovirus according to the present invention for use as a drug. The present invention further provides an adenovirus according to the present invention for use as a drug for the treatment of cancer. The adenovirus is propagated according to standard methods in the field of adenovirology and adenoviral vectors. A preferred method of propagation is by infecting a suitable cell line that allows the adenovirus to replicate. An example of a method for producing an adenovirus may further include harvesting the cells when they show a cytopathic effect indicative of virus production, and freezing and thawing the cells to produce a cell extract. The virus can be purified from the cell extract using standard techniques, such as banding in a cesium chloride gradient and dialysis, such as dialysis against phosphate buffered saline-10% glycerol. An alternative to CsCl is the Vivapure virus purification kit (Sartorius). The dialyzed and / or purified virus can be aliquoted and stored at -80°C. Quantification of the number of plaque-forming adenovirus particles and units is performed according to standard protocols. Phosphate-buffered saline containing 10% glycerol is the standard formulation for storage of adenovirus.

[0043] The adenovirus can be administered to an animal or human body to infect cells in vivo. Administration can be via several routes, including but not limited to, local injection into a tumor or a body cavity in which the tumor is located, injection into the blood circulation, inhalation, and application to the surface of a particular body area. After infection, the replication-competent adenovirus can replicate and spread to other cells under conditions in which the infected cells support the replication of the recombinant adenovirus. Thus, the replication-competent adenovirus can be used to reinfect new cells to further grow and spread the replication-competent adenovirus.

[0044] The adenovirus is preferably formulated in an aqueous or solution medium for preservation of viral particles that can be administered directly to an organism. The formulation preferably includes pharma- ceutically acceptable salts and excipients, such as human serum albumin, sugars, such as sucrose and mannitol, and / or surfactants, such as bifunctional block copolymer surfactants terminating in primary hydroxyl groups (Pluronic F68™).

[0045] In one embodiment, the replication-competent adenovirus according to the invention may further comprise one or more expression cassettes mediating the expression of one or more small or non-protein-coding RNA molecules, such as miRNA or shRNA, which may be specific for a p53 antagonist and / or an inhibitor of the p53 pathway in cells, or a combination thereof.

[0046] Previously, the inventors found that oncolysis and release of adenovirus progeny from infected cancer cells can be accelerated by restoring p53 function in the cancer cells (van Beusechem et al., Cancer Res. 62(2002):6165-6171; WO 03 / 057892, incorporated herein by reference). The restoration of p53 function is achieved by expressing in the cancer cells a restorer, i.e., a functional factor of the p53-dependent apoptosis pathway, which is not expressed or is poorly expressed in the cancer cells, and which preferably comprises a protein (WO 03 / 057892). Thus, the restorer is an essential positive component of the p53-dependent apoptosis pathway.

[0047] Loss of normal function of p53 is associated with resistance to programmed cell death, cell transformation in vitro, and the development of cancer in vivo. In approximately 50% of human cancers, the gene encoding p53 is nonfunctional due to deletion or mutation (Levine et al, Nature 351(1991):453-456; Hollstein et al, Science 253(1991):49-53; Chang et al, J. Clin. Oncol. 13(1995):1009-1022). In many of the other 50% of cancer cells that express wild-type p53 protein, p53 function is still disrupted by the action of p53 antagonists. An example of a p53 antagonist is MDM2. Loss of tumor suppressor protein p14ARF or overexpression of MDM2 protein can result in the inactivation of p53 function by binding to the MDM2 protein and subsequent degradation. In addition, even if p53 function itself is intact, p53-dependent cell death can be prevented by overexpression of anti-apoptotic proteins that act downstream from p53 on the p53 pathway, such as anti-apoptotic bcl-2 and IAP family members and BI-1. Another example is p73DeltaN, which binds to p53-responsive promoters and competes with p53, thereby antagonizing p53-dependent cell death (Kartasheva et al, Oncogene 21(2002):4715-4727). Expression of one or more RNAi-mediated molecules specific to one or more p53 antagonists and / or inhibitors of the p53 pathway or combinations thereof in cells will enhance lysogenic activity in target cells that contain functional p53.

[0048] The antagonist and / or inhibitor of the p53 pathway is preferably selected from synoviolin, MDM2, Pirh2, COP1, Bruce, HPV-E6, herpes virus 8 LANA, Parc, mortalin, Plk-1, BI-1, p73DeltaN, bcl-2, bcl-xL, bcl-w, bfl-1, brag-1, mcl-1, cIAP1, cIAP2, cIAP3, XIAP, and survivin. The expression cassette further comprises one or more expression control sequences functional in the host cell, such as an enhancer / promoter and terminator operably linked to the one or more RNAi-mediating molecules. Alternatively, the expression of one or more p53 antagonists and / or inhibitors of the p53 pathway or combinations thereof is operably linked to a regulatory element that mediates the expression of at least one DNA sequence that codes for a silencing factor that functions to reduce the expression of target genes in the host cell.It has been found that cancer cells contain more than one p53 antagonist and / or inhibitor of the p53 pathway.Such cells are more effectively lysed when they are given by RNAi against at least two of the p53 antagonists and / or inhibitors of the p53 pathway.

[0049] In a further embodiment, the replication-competent adenovirus according to the invention further comprises a DNA sequence encoding at least one restorer functioning to restore the p53-dependent apoptosis pathway in the host cell, operably linked to one or more expression control elements functional in the host cell. The restorer is preferably selected from apoptotic death-promoting genes of the bcl-2 family, such as bax, bak, bad, bid, bik, bim, bok, blk, hrk, puma, noxa, and bcl-xS (Miyashita and Reed, Cell 80(1995):293-299; Han et al., Genes Dev. 10(1996):461-477; Zoernig et al., Biochim. Biophys. Acta 1551(2001):F1-F37), and / or p53 or a functional part or derivative thereof. A preferred restorer functioning to restore the p53-dependent apoptosis pathway is p53.

[0050] The replication-competent adenovirus may further comprise a DNA sequence encoding a silencing factor that functions to reduce the expression and / or activity of POT1 in the cancer cell. The silencing factor is preferably an antisense RNA, such as RNAi or splice modulating oligonucleotide. Engineers are well competent to design suitable RNA-based silencing factors to reduce the expression of POT1 in the cancer cell. In the case of POT1, the cancer and / or cancer cell is preferably prostate cancer. It is further preferred that the treatment of prostate cancer further comprises irradiating the cancer.

[0051] Viral vectors are replication-deficient and require packaging cells to provide complementing genes that enable replication.

[0052] As used herein, adenoviral genome refers to the DNA sequences encoding the structural proteins and elements involved in the function / life cycle of the adenovirus.

[0053] A replication-competent adenovirus as defined herein is an adenovirus that contains as part of its genome the function to replicate in the host cell, where replication depends on the replication function provided by the virus in combination with the endogenous cellular machinery of the host cell. Therefore, the genome of the host cell does not need to have exogenous sequences that code for factors necessary for viral replication. The term "endogenous" in this context means that the cellular machinery (hence including the coding sequence) necessary for viral replication is a naturally occurring mechanism and has not been introduced into the cell, for example, by human engineering techniques. The latter is defined as "exogenous". As defined, replication functions are factors, e.g. proteins, encoded by the virus that are necessary for the replication of the virus in the host cell, and are also referred to herein as viral replication factors. It is important to note that these factors are encoded by the viral genome and do not need to be complemented by exogenous factors. Thus, a virus whose replication depends on one or more replication functions that are removed from the virus but introduced into the host cell is defined as replication-deficient and therefore is not part of the present invention. The claimed invention relates to replication competent viruses, i.e. viruses in which there are present on the viral genome viral genes encoding viral replication factors essential for the regulation of viral replication in the host cell, which is typically a cancer or cancer-like cell.

[0054] For clarity and conciseness of description, features have been described herein as part of the same or separate embodiments; however, it will be recognized that the scope of the invention may include embodiments having all or a partial combination of the described features. [Brief description of the drawings]

[0055] [Figure 1A]Adenoviruses expressing GSK3-beta inhibit the growth of human cancer cells in vitro but not primary non-malignant human cells in vitro. Figure 1A: Adenoviruses expressing GSK3-beta inhibit cancer cell proliferation in vitro. Adenoviruses expressing GSK3-beta (adGSK3b) inhibit the growth of four melanoma cell lines (SK-MEL-28, JUSO, MEL57, and WM9). As a control, a luciferase-expressing adenovirus (adLuc) was used. Cells were infected and followed in culture for 8 days: pictures of the wells were taken every 4 hours by IncuCyte. [Figure 1B] Adenoviruses expressing GSK3-beta inhibit the growth of human cancer cells in vitro, but not primary non-malignant human cells in vitro. Figure 1B: GSK3-beta expression does not affect the growth of normal primary fibroblasts. Adenoviruses expressing GSK3-beta do not inhibit the growth of non-transformed primary human fibroblasts. As a control, the cancer cell line JUSO is run alongside, which is growth inhibited. [Figure 1C] Adenovirus expressing GSK3-beta inhibits the growth of human cancer cells in vitro, but not primary non-malignant human cells in vitro. Figure 1C: Photograph of primary fibroblasts 6 days after infection with ad.LUC or ad.CA.GSK3-beta. [Figure 2A] Induction of cell apoptosis in different melanoma cell lines by transduction with ad.CA.GSK3-beta. FIG. 2A: Cancer cells infected with Ad.CA.GSK3-beta are visibly affected at day 1 and have a more rounded phenotype indicating the onset of cell death. At day 3, the number of Caspase 3 / 7 positive cells (green) increases. At day 6, cancer cells with ad.CA.GSK3b are mostly positive for apoptosis markers, while cancer cells transduced with control virus hardly show any apoptotic cells. SK-MEL-28 cell line data is shown as an example. [Figure 2B1] Induction of cell apoptosis in different melanoma cell lines by transduction with ad.CA.GSK3-beta. FIG. 2B: Relative apoptosis of different melanoma cell lines at different time points comparing the effect of cells transduced with ad.LUC vs. ad.CA.GSK3-beta. Ad.CA.GSK3-beta induced apoptosis faster than Ad.LUC, demonstrating the oncolytic effect of infecting melanoma cells with an adenovirus expressing a constitutively active form of GSK3-beta. [Figure 2B2] Induction of cell apoptosis in different melanoma cell lines by transduction with ad.CA.GSK3-beta. FIG. 2B: Relative apoptosis of different melanoma cell lines at different time points comparing the effect of cells transduced with ad.LUC vs. ad.CA.GSK3-beta. Ad.CA.GSK3-beta induced apoptosis faster than Ad.LUC, demonstrating the oncolytic effect of infecting melanoma cells with an adenovirus expressing a constitutively active form of GSK3-beta. [Figure 2B3] Induction of cell apoptosis in different melanoma cell lines by transduction with ad.CA.GSK3-beta. FIG. 2B: Relative apoptosis of different melanoma cell lines at different time points comparing the effect of cells transduced with ad.LUC vs. ad.CA.GSK3-beta. Ad.CA.GSK3-beta induced apoptosis faster than Ad.LUC, demonstrating the oncolytic effect of infecting melanoma cells with an adenovirus expressing a constitutively active form of GSK3-beta. [Figure 2B4]Induction of cell apoptosis in different melanoma cell lines by transduction with ad.CA.GSK3-beta. FIG. 2B: Relative apoptosis of different melanoma cell lines at different time points comparing the effect of cells transduced with ad.LUC vs. ad.CA.GSK3-beta. Ad.CA.GSK3-beta induced apoptosis faster than Ad.LUC, demonstrating the oncolytic effect of infecting melanoma cells with an adenovirus expressing a constitutively active form of GSK3-beta. [Diagram 3] Adenovirus expressing GSK3-beta selectively induces cancer cell death in primary melanoma tumor suspensions. [Figure 4A] Expression of GSK3-beta enhances adenovirus replication.Figure 4A shows uninfected 911 cells and their growth kinetics, reaching confluency on day 3. [Figure 4B] Expression of GSK3-beta enhances adenovirus replication. Figure 4B shows 911 cells infected with ad.LUC at 1 MOI, resulting in complete cytopathic effect (CPE) at day 3.5 (84 hours post-infection). [Figure 4C] Expression of GSK3-beta enhances adenovirus replication Adenovirus expressing GSK3-beta (ad.CA.GSK3-beta) caused complete CPE at day 1 post-infection (FIG. 4C). [Diagram 5] Schematic diagram of a DNA construct encoding the ORCA-10 virus described in Dong et al. (2014, Human Gene Therapy 25: 897-904), a schematic diagram of a homologous recombination construct comprising the coding region of GSK3 beta S9A under the control of a CMV promoter; and a schematic diagram of a recombinant construct comprising the ORCA-10 virus having the coding region of GSK3 beta S9A under the control of a CMV promoter. [Figure 6]Schematic diagram of a DNA construct encoding the ORCA-10 virus described in Dong et al. (2014, Human Gene Therapy 25: 897-904), a schematic diagram of a homologous recombination construct comprising a coding region of GSK3 beta S9A under the control of an SV40 promoter; and a schematic diagram of a recombinant construct comprising an ORCA-10 virus having a coding region of GSK3 beta S9A under the control of an SV40 promoter. [Figure 7] Schematic diagram of a DNA construct encoding the ORCA-10 virus described in Dong et al. (2014, Human Gene Therapy 25: 897-904), a schematic diagram of a homologous recombination construct containing a coding region for rLuc under the control of a CMV promoter, a luciferase coding region; and a schematic diagram of a recombinant construct containing the ORCA-10 virus with the coding region for rLuc under the control of the CMV promoter mentioned.

[0056] Working Example In the figures and examples, different names are used to refer to the same virus. Adenoviruses carrying the GSK3-beta S9A coding region are called adGSK3b; ad.CA.GSK3-beta; Ad.CA.GSK3-beta; and ad.CA.GSK3-beta S9A, etc. Adenoviruses carrying the reference luciferase coding region are called ad.LUC; Ad.LUC, and Ad.Luc, etc.

[0057] Example 1. Adenovirus expressing GSK3-beta inhibits the growth of human cancer cells but not non-malignant primary human cells in vitro. To evaluate the effect of adenovirus expressing GSK3-beta on cancer and non-malignant cells, we cultured four different melanoma cell lines (SK-MEL-28, JUSO, MEL57, and WM9) and primary skin-derived fibroblasts (Fibro) freshly isolated from healthy skin.

[0058] Cells were cultured in complete RPMI medium (RPMI HEPES and L-glutamine medium (Lonza) supplemented with 10% heat-inactivated FCS (HyClone), 100 IU / mL sodium penicillin, 100 ug / mL streptomycin, 2 mM L-glutamine, and 50 uM beta-mercaptoethanol). Cells (SK-MEL-28, JUSO, MEL57, WM9, or Fibro) were seeded in 96-well plates (10,000 cells per well). 24 hours after seeding, cells were infected with either Ad.LUC (Ad5Luc1, (ref 17) Krasnykh et al. J. of Virology, 75 (2001):4176-4183) or Ad.CA.GSK3-beta (Kim et al. (ref 18) J. of Bio. Chemistry, 277 (2002):41888-41896) at a multiplicity of infection (MOI) of 500. Cells were incubated at 37°C and 5% CO2 in an IncuCyte Zoom (EssenBioscience) and followed for 8 days in culture. Photographs of the wells were taken every 4 hours by IncuCyte zoom. IncuCyte Zoom software was used to analyze the wells and confluence masks were applied by the software to obtain the percentage of confluence per well at the different measurement time points. Confluency data was plotted on a graph using Graphpad Prism (Graphpad).

[0059] The infectious titer of the virus was determined by titration of the virus in 911 cells using the Adeno-X rapid titration kit (BD Clontech). 500 MOI refers to 500 infectious virus particles per cell as determined by virus titration using the Adeno-X rapid titration kit.

[0060] Results demonstrated that cancer cells infected with GSK3-beta expressing virus were growth inhibited and that the number of cells began to decrease (indicating cell death) 3-4 days after infection (Figure 1A). In contrast, luciferase expressing virus did not inhibit the growth of the cancer cells and the wells became confluent at approximately day 4. As shown in Figures 1B and 1C, this is a specific anti-cancer effect, as primary human fibroblasts were not growth inhibited by infection with Ad.CA.GSK3-beta.

[0061] Taken together, these data demonstrate that adenoviral-enforced expression of a constitutively active form of GSK-beta kills cancer cells, whereas it does not show any effect on primary fibroblasts.

[0062] Example 2. Induction of apoptosis in human melanoma cell lines by transduction with Ad.CA.GSK3-beta To demonstrate that ad.CA.GSK3-beta can induce cancer cell death, 10,000 melanoma cells (SK-MEL-28, JUSO, Mel57, or WM9) were seeded in complete RPMI medium in 96-well plates. 24 hours after seeding, the cells were infected with 500 MOI of Ad.LUC or Ad.CA.GSK3-beta with 1:1000 FITC-caspase 3 / 7 reagent (IncuCyte) according to the manufacturer's protocol. Cells were incubated in an IncuCyte Zoom at 37°C and 5% CO2 for 8 days. Photographs of the wells were taken by IncuCyte every 4 hours. IncuCyte Zoom software was used to analyze the data, and a confluence mask and a green confluence mask were applied by the software to obtain the percentage of confluence per well and the percentage of green signal in the well, respectively. The percentage of apoptotic cells was determined by dividing the green mask value by the confluence value at different time points.

[0063] Over a period of 6 days, the percentage of caspase 3 / 7 positive cells (apoptotic cells) increased more rapidly in cultures infected with Ad.CA.GSK3-beta compared to cultures infected with Ad.LUC (Figure 2A and Figure 2B). At day 1, there is a clear effect on the morphology of SK-MEL-28 cells when infected with Ad.CA.GSK3-beta in contrast to the control virus (Ad.LUC) (Figure 2A). At day 3, some caspase 3 / 7 positive staining cells (indicated by green label) can be observed in cultures with Ad.CA.GSK3-beta. At day 6, SK-MEL-28 transduced with Ad.CA.GSK3-beta were mostly positive for apoptotic markers, while cancer cells transduced with the control virus hardly showed any apoptotic cells.

[0064] These data demonstrated that adenoviral forced expression of constitutively active GSK3-beta promotes apoptosis in cancer cells.

[0065] Example 3. Adenovirus expressing GSK3-beta induces selective cancer cell death in metastatic melanoma tumor suspensions To demonstrate the anti-tumor effect of adenoviral delivered GSK3-beta, metastatic melanoma tumor cell suspensions were infected with Ad.LUC or Ad.CA.GSK3-beta.

[0066] Viable tumor tissue was obtained from melanoma patients. Samples were then minced with a scalpel and dissociated in HBSS (Whittaker Bioproducts) containing 0.1% DNase type I and 0.14% collagenase type I (Sigma Chemical). Single cell suspensions were then frozen in aliquots of 15-20 million cells per mL with 10% DMSO in a controlled rate freezer and stored in liquid nitrogen until use.

[0067] Melanoma cell suspensions were thawed and 1,200,000 metastatic melanoma tumor cells were cultured in complete RPMI in 6-well plates and infected with 500 MOI of Ad.LUC or Ad.CA.GSK3-beta after 4 hours. The cells were then incubated at 37° C. and 5% CO2 for 5 days. After 5 days, samples were collected (centrifugation at 1560 rpm for 5 minutes) and washed with PBS supplemented with 0.1% bovine serum albumin (BSA) and 0.02% sodium azide and 0.1% BSA in PBS (FACS buffer) and centrifuged at 1560 rpm for 5 minutes. The supernatant was then removed, leaving a cell pellet in approximately 50 microliters of supernatant. Cells were resuspended in the remaining supernatant and stained for surface markers CD45 (AF700, Biolegend) and MCSP (APC, Miltenyi biotec) for 30 min at 4° C. After incubation, antibody excess was removed by washing with FACS buffer. Samples were analyzed using a Fortessa flow cytometer (BD Bioscience) and Kaluza analysis software (Beckman).

[0068] The results of this analysis are shown in Figure 3. Cells were stained with the CD45 marker to distinguish melanoma cells from healthy immune cells in the tumor microenvironment. Immune cells (gated in purple) are positive for CD45, whereas tumor cells are negative. In addition, the MCSP marker was added to actually distinguish cancer cells from healthy non-immune cells (e.g., fibroblasts). MCSP is a known melanoma marker, and therefore melanoma cells will be MCSP+CD45- cells (gated in orange). Nevertheless, it is important to note that the MCSP-CD45- cell fraction (gated in blue) may contain not only healthy non-immune cells, but also some melanoma cells that probably do not express the MCSP marker (not all melanoma cells are positive for the same marker, there is donor variability in this regard).

[0069] When the melanoma cell suspension was transduced with Ad.CA.GSK3-beta, the relative percentage of melanoma cells after 5 days was 1.72%. In contrast, in the Ad.LUC-infected melanoma suspension, the relative percentage of viable melanoma cells was 21.65%. Furthermore, the immune cells appeared to remain unaffected by the presence of Ad.CA.GSK3-beta, with a viability of 50.77% for Ad.LUC and 64.29% for Ad.CA.GSK3-beta, further demonstrating the tumor specificity of Ad.CA.GSK3-beta. Other cells (CD45-MCSP-, mostly healthy non-immune cells such as fibroblasts) were also unaffected by transduction with adenovirus encoding constitutively active GSK3-beta.

[0070] The results demonstrate the feasibility of utilizing adenoviral delivery of a constitutively active form of GSK3-beta to induce specific cancer cell death.

[0071] Example 4. Expression of GSK3-beta enhances adenovirus replication Ad.CA.GSK3-beta and Ad.LUC are replication-deficient adenoviral vectors. To test the effect of constitutively active GSK3-beta in the context of replication-competent adenovirus, experiments in 911 cells, a cell line that complements replication-deficient adenovirus for adenovirus replication, were performed (Figure 4).

[0072] Replication-deficient Ad.LUC or Ad.CA.GSK3-beta was amplified in 911 cells (a cell line that complements adenovirus replication). 911 cells (Fallaux FJ et al. Hum Gene Ther., (1992): 215-22) were cultured in complete RPMI. On day 1, 911 cells were seeded (10000 cells / well) in 96-well plates and infected 6 hours later with ad.LUC or ad.CA.GSK3-beta at MOI 1. As a negative infection control, uninfected 911 cells were used. Cells were incubated at 37°C and 5% CO2 in an IncuCyte Zoom and followed for 5 days. Photographs of the wells were taken at different intervals by IncuCyte. The results demonstrated that Ad.LUC induced visible CPE (cytopathic effect) at approximately day 3 post-infection (Figure 4B), whereas GSK3-beta expressing virus (Ad.CA.GSK3-beta) showed CPE already at day 1 (Figure 4C), demonstrating the synergistic cytotoxic effect of GSK3-beta and replication-competent adenovirus. The MOI used in this experiment was one infectious virus particle per cell (1 MOI). Therefore, most likely, not all cells were infected with virus particles from the inoculum. Taken together with the defect in cell proliferation in Ad.CA.GSK3-beta infected cells, this indicates that the presence of constitutively active GSK3-beta accelerates viral replication or release, a desirable feature for oncolytic virotherapy.

[0073] Example 5. Methods for constructing replication-competent adenovirus expressing GSK3-beta Replication-competent adenovirus containing GSK3b between E4 and the right ITR of the adenovirus genome can be generated in different cloning steps as follows: An adenovirus shuttle vector carrying a GSK3b expression cassette is generated. In a second step, this shuttle vector is linearized and recombined with full-length linearized adenovirus DNA (e.g., ORCA-010; an oncolytic virus carrying E1A delta 24, T1 mutation, and fiber RGD insertion). The GSK3-beta DNA sequence will contain a serine to alanine mutation at position 9 and an HA (hemagglutinin) tag sequence at the C-terminal region.

[0074] GSK3-beta expression cassette The GSK3-beta expression cassette contains the following sequence: The expression cassette is made by DNA synthesis (GeneArt Gene Synthesis, ThermoFisher Scientific). The expression cassette is cloned into the pMK cloning vector (ThermoFisher Scientific) using the EcoRI restriction site.

[0075] CMV-GSK3-betaHA-pA

[0076] EcoRI site GAATTC-

[0077] SpeI site ACTAGT-

[0078] CMV Enhancer GACATTGATTATTGACAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGA CGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATG-

[0079] CMV promoter GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCCCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCT-

[0080] Sequence containing the I-CeuI restriction site CGTAACTATAACGGTCCTAAGGTAGCGAAA-

[0081] HA-tagged GSK3 beta sequence (HA tag sequence is italicized and underlined) [ka]

[0082] Poly A TGGATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGATATGGCTGAT-

[0083] SpeI site ACTAGT

[0084] EcoRI site GAATTC-

[0085] Construction of a shuttle vector carrying a GSK3-beta expression cassette As shuttle vector backbone, pEndK / Spel vector (provided by Dr. R. Alemany, Institut Catala d'Oncologia, Barcelona, ​​Spain) is used. pEndK / Spel was generated by KpnI digestion of vector pTG3602 (Chartier et al., J. Virol, 70(1996):4805-4810) and religation of the vector fragment containing Ad5 map units 0-7 and 93-100 to generate pEndK. A Spel site was introduced into pEndK by changing Ad5 nucleotide 35813 from A to T by site-directed mutagenesis to generate pEndK / Spel. pEndK / Spel has PacI restriction sites flanking the two Ad5 ITRs.

[0086] The GSK3-beta expression cassette generated by DNA synthesis is cloned into pEndK / SpeI using the SpeI restriction site to generate pEndK / SpeI-GSK3 beta. Correct pEndK / SpeI-GSK3-beta clones can be identified by restriction analysis using different restriction enzymes present in the vector (e.g., I-CeuI unique restriction site).

[0087] Recombination to generate a full-length adenoviral genome with GSK3-beta Plasmid pEndK / SpeI-GSK3beta is linearized with KpnI. The linearized plasmid can be recombined with replication-competent full-length adenoviral DNA (e.g., ORCA-010) in bacteria (e.g., BJ5183) or yeast (e.g., YPH857).

[0088] The full-length adenoviral DNA can be isolated from adenoviral particles or, alternatively, can be released by restriction enzyme digestion from a plasmid carrying a full-length adenoviral DNA insert.

[0089] Homologous recombination produces a plasmid with a full-length adenoviral genome, in which the GSK3-beta expression cassette is inserted between the E4 region and the right ITR.It should be noted that according to this method, any replication-competent adenovirus can be used to insert the GSK3b expression cassette, including recombinant adenoviruses with additional modifications, such as E3 deletion, enhanced tumor selectivity or tumor lysis ability, altered tropism, or transgene insertion.However, it is preferred that the replication-competent full-length adenoviral genome does not contain a PacI restriction site in its genome.

[0090] Virus production Subsequently, the replication-competent adenovirus genome with the inserted GSK3b expression cassette is released from the plasmid by PacI digestion. This DNA is transfected into human cells, e.g., A549, cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS (Hyclone) and 100 U / mL Pen / Strep, using, e.g., Lipofectamine reagent. The resulting replication-competent recombinant adenovirus according to the present invention is isolated and further propagated and purified according to standard cell culture and virology methods known in the art.

[0091] Example 6. Methods for constructing replication-competent adenovirus expressing GSK3-beta As in Example 5, the GSK3-beta expression cassette has the following sequence:

[0092] SV40-GSK3-betaHA-pA

[0093] EcoRI site GAATTC-

[0094] SpeI site ACTAGT-

[0095] SV40 promoter GGTGTGGAAAGTCCCCAGGCTCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAA CTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAA-

[0096] Sequence containing the I-CeuI restriction site CGTAACTATAACGGTCCTAAGGTAGCGAAA-

[0097] HA-tagged GSK3 beta sequence (HA tag sequence is italicized and underlined) [ka]

[0098] Poly A TGGATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGATATGGCTGAT-

[0099] SpeI site ACTAGT

[0100] EcoRI site GAATTC-

[0101] Example 7. Methods for constructing replication-competent adenovirus expressing luciferase As a control, a conditionally replication competent oncolytic virus expressing luciferase can be made using the same methodology as in Example 5 or 6, with the DNA-synthesized HA-tagged GSK3-beta sequence in the expression cassette replaced by the luciferase sequence described below.

[0102] Renilla luciferase sequence ATGACTTCGAAAGTTTATGATCCAGAACAAAGGAAACGGATGATAACTGGTCCGCAGTGGTGGGCCAGATGTAAACAAATGAATGTTCTTGATTCATTTATTAATTATTATGATTCAGAAAAACATGCAGAAAATGCTGTTATTTTTTTACATGGTAACGCGGCCTCTTCTTATTTATGGCGACATGTTGTGCCACATATTGAGCCAGTAGCGCGGTGTATTATACCAGACCTTATTGGTATGGGCAAATCAGGCAAATCTGGTAATGGTTCTTATAGGTTACTTGATCATTACAAATATCTTACTGCATGGTTTGAACTTCTTAATTTACCAAAGAAGATCATTTTTGTCGGCCATGATTGGGGTGCTTGTTTGGCATTTTATTATAGCTATGAGCATCAAGATAAGATCAAAGCAATAGTTCACGCTGAAAGTGTAGTAGATGTGATTGAATCATGGGATGAATGG CCTGATATTGAAGAAGATATTGCGTTGATCAAATCTGAAGAAGGAGAAAAAATGGTTTTGGAGAATAACTTCTTCGTGGAAACCATGTTGCCATCAAAAATCATGAGAAAGTTAGAACCAGAAGAATTTGCAGCATATCTTGAACCATTCAAAGAGAAAGGTGAAGTTCGTCGTCCAACATTATCATGGCCTCGTGAAATCCCGTTAGTAAAAGGTGGTAAACCTGACGTTGTACAAATTGTTAGGAATTATAATGCTTATCTACGTGCAAGTGATGATTTACCAAAAATGTTTATTGAATCGGACCCAGGATTCTTTTCCAATGCTATTGTTGAAGGTGCCAAGAAGTTTCCTAATACTGAATTTGTCAAAGTAAAAGGTCTTCATTTTTCGCAAGAAGATGCACCTGATGAAATGGGAAAATATATCAAATCGTTCGTTGAGCGAGTTCTCAAAAATGAACAATAA

[0103] Example 8. Methods for assessing the oncolytic potency of replication-competent adenoviruses expressing GSK3-beta The oncolytic potency of the replication-competent adenovirus expressing GSK3-beta produced in Examples 5 and 6 is compared to its relevant control (promoter-based), the replication-competent adenovirus expressing luciferase produced in Example 7. Alternatively, other already available conditionally replication-competent full-length adenoviruses expressing luciferase under the CMV or SV40 promoter can also be used.

[0104] To compare the oncolytic efficacy of different viruses, cytotoxicity assays are carried out in human cancer cell lines. Different cancer cell lines (e.g., Hep3B, A549, U2OS, HCT 116, SK-MEL-28, UM-SCC-22A, LNCaP, NP9, DU-145, UM-SCC-11B, UM-SCC-14C, PC-3, VU1131, MDA-MB-231, and / or FaDu) can be used for the assay. Cytotoxicity assays are carried out according to Dong et al. (Human Gene Therapy 25 (2014): 897-904) using the viruses produced in Examples 5, 6 and 7.

[0105] This work was funded in part by the European Union Horizon 2020 research and innovation programme, Marie Sklodowska-Curie grant number 643130.

[0106] References JPEG2024161491000003.jpg237170JPEG2024161491000004.jpg86170

[0107] Some sequences [Sequence List Free Text]

[0108] <210> 1 <211> 484 <212> DNA <213> Artificial sequence <220> <223> Mutant of codifying region for protein E3-19K of human adenovirus serotype 5 <400> 1 atgattaggt acataatcct aggtttactc acccttgcgt cagcccacgg taccacccaa 60 aaggtggatt ttaaggagcc agcctgtaat gttacattcg cagctgaagc taatgagtgc 120 accactctta taaaatgcac cacagaacat gaaaagctgc ttattcgcca caaaaacaaa 180 attggcaagt atgctgttta tgctatttgg cagccaggtg acactacaga gtataatgtt 240 acagttttcc agggtaaaag tcataaaact tttatgtata cttttccatt ttatgaaatg 300 tgcgacatta ccatgtacat gagcaaacag tataagttgt ggcccccaca aaattgtgtg 360 gaaaacactg gcactttctg ctgcactgct atgctaatta cagtgctcgc tttggtctgt 420 accctactct atattaaata caaaaagcag acgcagcttt attgaggaaa agaaaatgcc 480 ttaa 484 <210> 2 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Fragment of mutated carboxy-terminal fragment of protein E3-19K of human adenovirus type 5 <400> 2 Lys Lys Gln Thr Gln Leu Tyr 1 5 <210> 3 <211> 483 <212> DNA <213> Artificial sequence <220> <223> Mutant of codifying region for protein E3-19K of human adenovirus type 5 <400> 3 atgattaggt acataatcct aggtttactc acccttgcgt cagcccacgg taccacccaa 60 aaggtggatt ttaaggagcc agcctgtaat gttacattcg cagctgaagc taatgagtgc 120 accactctta taaaatgcac cacagaacat gaaaagctgc ttattcgcca caaaaacaaa 180 attggcaagt atgctgttta tgctatttgg cagccaggtg acactacaga gtataatgtt 240 acagttttcc agggtaaaag tcataaaact tttatgtata cttttccatt ttatgaaatg 300 tgcgacatta ccatgtacat gagcaaacag tataagttgt ggcccccaca aaattgtgtg 360 gaaaacactg gcactttctg ctgcactgct atgctaatta cagtgctcgc tttggtctgt 420 accctactct atattaaata caaaagcaga cgcagcttta ttgaggaaag cagcatgcct 480 taa 483 <210> 4 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Fragment of mutated carboxy-terminal fragment of protein E3-19K of human adenovirus type 5 <400> 4 Lys Ser Arg Arg Ser Pro Ile Glu Glu Ser Ser Met Pro 1 5 10 <210> 5 <211> 2512 <212> DNA <213> Artificial sequence <220> <223> Sequence with the regulatory regions DM1 insulator (from position 367 to 1095); a fragment of the E2F1 promoter (from position 1282 to 1545); the ccacc kozak sequence (from position 1546 to 1550); and the E1a- 24 gene (from position 1551 to 2512). <400> 5 catcatcaat tataccttcc attttggatt gaagccaata tgataatgag ggggtggagt 60 ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120 gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180 gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtag 240 taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300 agtgaaatct gaataatttt gtgttactca tagcgcgtaa tctctagcat cgatgtcgag 360 gatccctcga gaccctgaaa ctgtcttcga ctccggggcc ccgttggaag actgagtgcc 420 cggggcacgg cacagaagcc gcgcccaccg cctgccagtt cacaaccgct ccgagcgtgg 480 gtctccgccc agctccagtc ctgtgatccg ggcccgcccc ctagcggccg gggagggagg 540 ggccgggtcc gcggccggcg aacggggctc gaagggtcct tgtagccggg aatgctgctg 600 ctgctgctgg ggggatcaca gaccatttct ttctttcggc caggctgagg ccctgacgtg 660 gatgggcaaa ctgcaggcct gggaaggcag caagccgggc cgtccgtgtt ccatcctcca 720 cgcaccccca cctatcgttg gttcgcaaag tgcaaagctt tcttgtgcat gacgccctgc 780 tctggggagc gtctggcgcg atctctgcct gcttactcgg gaaatttgct tttgccaaac 840 ccgctttttc ggggatcccg cgcccccctc ctcacttgcg ctgctctcgg agccccagcc 900 ggctccgccc gcttcggcgg tttggatatt tattgacctc gtcctccgac tcgctgacag 960 gctacaggac ccccaacaac cccaatccac gttttggatg cactgagacc ccgacattcc 1020 tcggtattta ttgtctgtcc ccacctagga cccccacccc cgaccctcgc gaataaaagg 1080 ccctccatct gcccctcgag tctagagatg gccgcaataa aatatcttta ttttcattac 1140 atctgtgtgt tggttttttg tgtgaatcga tagtactaac atacgctctc catcaaaaca 1200 aaacgaaaca aaacaaacta gcaaaatagg ctgtccccag tgcaagtgca ggtgccagaa 1260 catttctcta tcgataggta ccatccggac aaagcctgcg cgcgccccgc cccgccattg 1320 gccgtaccgc cccgcgccgc cgccccatct cgcccctcgc cgccgggtcc ggcgcgttaa 1380 agccaatagg aaccgccgcc gttgttcccg tcacggccgg ggcagccaat tgtggcggcg 1440 ctcggcggct cgtggctctt tcgcggcaaa aaggatttgg cgcgtaaaag tggccgggac 1500 tttgcaggca gcggcggccg ggggcggagc gggatcgagc cctcgccacc atgagacata 1560 ttatctgcca cggaggtgtt attaccgaag aaatggccgc cagtcttttg gaccagctga 1620 tcgaagaggt actggctgat aatcttccac ctcctagcca ttttgaacca cctacccttc 1680 acgaactgta tgatttagac gtgacggccc ccgaagatcc caacgaggag gcggtttcgc 1740 agatttttcc cgactctgta atgttggcgg tgcaggaagg gattgactta ctcacttttc 1800 cgccggcgcc cggttctccg gagccgcctc acctttcccg gcagcccgag cagccggagc 1860 agagagcctt gggtccggtt tctatgccaa accttgtacc ggaggtgatc gatccaccca 1920 gtgacgacga ggatgaagag ggtgaggagt ttgtgttaga ttatgtggag caccccgggc 1980 acggttgcag gtcttgtcat tatcaccgga ggaatacggg ggacccagat attatgtgtt 2040 cgctttgcta tatgaggacc tgtggcatgt ttgtctacag taagtgaaaa ttatgggcag 2100 tgggtgatag agtggtgggt ttggtgtggt aatttttttt ttaattttta cagttttgtg 2160 gtttaaagaa ttttgtattg tgattttttt aaaaggtcct gtgtctgaac ctgagcctga 2220 gcccgagcca gaaccggagc ctgcaagacc tacccgccgt cctaaaatgg cgcctgctat 2280 cctgagacgc ccgacatcac ctgtgtctag agaatgcaat agtagtacgg atagctgtga 2340 ctccggtcct tctaacacac ctcctgagat acacccggtg gtcccgctgt gccccattaa 2400 accagttgcc gtgagagttg gtgggcgtcg ccaggctgtg gaatgtatcg aggacttgct 2460 taacgagcct gggcaacctt tggacttgag ctgtaaacgc cccaggccat aa 2512 <210> 6 <211> 1773 <212> DNA <213> Artificial sequence <220> <223> Sequence codifying the fiber of the human adenovirus type 5 (from position 1 to 1638; and position 1666 to 1773) containing an insertion of the peptide RGD (from position 1639 to 1665) containing the RGD motif (from 1648 to 1656). <400> 6 atgaagcgcg caagaccgtc tgaagatacc ttcaaccccg tgtatccata tgacacggaa 60 accggtcctc caactgtgcc ttttcttact cctccctttg tatcccccaa tgggtttcaa 120 gagagtcccc ctggggtact ctctttgcgc ctatccgaac ctctagttac ctccaatggc 180 atgcttgcgc tcaaaatggg caacggcctc tctctggacg aggccggcaa ccttacctcc 240 caaaatgtaa ccactgtgag cccacctctc aaaaaaacca agtcaaacat aaacctggaa 300 atatctgcac ccctcacagt tacctcagaa gccctaactg tggctgccgc cgcacctcta 360 atggtcgcgg gcaacacact caccatgcaa tcacaggccc cgctaaccgt gcacgactcc 420 aaacttagca ttgccaccca aggacccctc acagtgtcag aaggaaagct agccctgcaa 480 acatcaggcc ccctcaccac caccgatagc agtaccctta ctatcactgc ctcaccccct 540 ctaactactg ccactggtag cttgggcatt gacttgaaag agcccattta tacacaaaat 600 ggaaaactag gactaaagta cggggctcct ttgcatgtaa cagacgacct aaacactttg 660 accgtagcaa ctggtccagg tgtgactatt aataatactt ccttgcaaac taaagttact 720 ggagccttgg gttttgattc acaaggcaat atgcaactta atgtagcagg aggactaagg 780 attgattctc aaaacagacg ccttatactt gatgttagtt atccgtttga tgctcaaaac 840 caactaaatc taagactagg acagggccct ctttttataa actcagccca caacttggat 900 attaactaca acaaaggcct ttacttgttt acagcttcaa acaattccaa aaagcttgag 960 gttaacctaa gcactgccaa ggggttgatg tttgacgcta cagccatagc cattaatgca 1020 ggagatgggc ttgaatttgg ttcacctaat gcaccaaaca caaatcccct caaaacaaaa 1080 attggccatg gcctagaatt tgattcaaac aaggctatgg ttcctaaact aggaactggc 1140 cttagttttg acagcacagg tgccattaca gtaggaaaca aaaataatga taagctaact 1200 ttgtggacca caccagctcc atctcctaac tgtagactaa atgcagagaa agatgctaaa 1260 ctcactttgg tcttaacaaa atgtggcagt caaatacttg ctacagtttc agttttggct 1320 gttaaaggca gtttggctcc atatctgga acagttcaa gtgctcatct tattataga 1380 tttgacgaaa atggagtgct actaaacaat tccttcctgg acccagaata ttggaacttt 1440 agaaatggag atcttactga aggcacagcc tatacaacg ctgttggatt tatgcctaac 1500 ctatcagctt atccaaatc tcacggtaaa actgccaaaa gtaacattgt cagtcaagtt 1560 tacttaacg gagacaaac taaacctgta acactaacga tcacactaa cggtacacag 1620 gaaacaggag accaacttg tgactgccgc ggagactgtt tctgccatc tgcatactct 1680 atgtcatttt catgggactg gtctggccac aactacatta atgaaatatt tgccacatcc 1740 the lizard licks the lizard 1773

[0109] JPEG2024161491000005.jpg223158

[0110] JPEG2024161491000006.jpg223158

[0111] JPEG2024161491000007.jpg223158

[0112] JPEG2024161491000008.jpg223158

[0113] JPEG2024161491000009.jpg223158

[0114] JPEG2024161491000010.jpg223158

[0115] JPEG2024161491000011.jpg223158

[0116] JPEG2024161491000012.jpg223158

[0117] JPEG2024161491000013.jpg223158

[0118] JPEG2024161491000014.jpg223158

Claims

1. A replication-competent recombinant adenovirus comprising within its genome a coding sequence for glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence.

2. The adenovirus of claim 1, comprising a modification that enables preferential replication of the adenovirus in tumor cells.

3. The adenovirus of claim 2 , wherein the modification comprises a mutation in the E1a gene, the E1b gene or both genes.

4. The adenovirus of claim 2 or 3, wherein the modification comprises a promoter for tumor-specific expression of E1A or E1B.

5. The adenovirus according to any one of claims 2 to 4, wherein the modification comprises a promoter for tissue or cell type specific expression of E1A or E1B.

6. The adenovirus according to any one of claims 1 to 5, which comprises a modification of the nucleic acid sequence in the E3 region.

7. The adenovirus according to any one of claims 1 to 6, wherein the adenovirus is an oncolytic adenovirus.

8. The adenovirus according to any one of claims 1 to 7, wherein the GSK3 protein is a GSK3 beta protein.

9. The adenovirus according to any one of claims 1 to 8, wherein the GSK3 protein is a constitutively active mutant protein.

10. 10. The adenovirus according to claim 9, wherein said GSK3 protein is a GSK3 beta protein in which the serine residue at position 9 is replaced by another amino acid residue, preferably an alanine residue.

11. A method of treating cancer in an individual, comprising administering to an individual in need of said treatment a nucleic acid molecule comprising a coding sequence for Glycogen Synthase Kinase-3 (GSK3) protein operably linked to an expression control sequence.

12. 12. The method of claim 11, wherein the cancer does not express or overexpress active GSK3, preferably GSK3 beta.

13. 13. The method of claim 11 or 12, comprising administering a recombinant virus comprising a nucleic acid sequence comprising a coding sequence for Glycogen Synthase Kinase-3 (GSK3) protein operably linked to an expression control sequence, preferably the recombinant virus is a recombinant adenovirus.

14. The method according to claim 13, wherein the adenovirus is an adenovirus according to any one of claims 1 to 10.

15. A method of killing a cancer cell, comprising providing to the cancer cell a nucleic acid molecule comprising a coding sequence for Glycogen Synthase Kinase-3 (GSK3) protein operably linked to an expression control sequence.

16. A method for increasing the replication rate of a replication-competent recombinant adenovirus in a permissive cell, the method comprising providing a coding sequence for a GSK3 protein operably linked to an expression control sequence to the genome of the adenovirus so as to express the coding sequence in the cell.

17. A method for increasing the oncolytic properties of a replication-competent oncolytic recombinant adenovirus, comprising providing a coding sequence for a GSK3 protein operably linked to an expression control sequence to the genome of the adenovirus for expression.

18. A method for increasing the rate of replication and spread of a replication-competent recombinant adenovirus in a tumor, comprising providing an oncolytic virus with a coding sequence for a GSK3 protein operably linked to an expression control sequence for expression in cells of the tumor.

19. A method of using a coding sequence for a GSK3 protein operably linked to an expression control sequence, said coding sequence being used to express said coding sequence to increase the rate of replication of a recombinant adenovirus.

20. The adenovirus according to any one of claims 1 to 10, further comprising a coding region for a further transgene, preferably IL2, GM-CSF and / or TNF-alpha.

21. A combination comprising an adenovirus according to any one of claims 1 to 10 and 20 and a further medicament.

22. 22. The combination of claim 21 , wherein the further medicament comprises an antibody, preferably a bispecific antibody.

23. 16. The method or adenoviral vector for said method according to any one of claims 11 to 15, further comprising the administration of concurrent or sequential radiation therapy, antibody therapy, chemotherapy, cell therapy, immunotherapy, or other anti-cancer intervention or treatment.